Answer
The treatment targets a pathway driven by PIK3CA mutations, and the licence requires confirmation of an eligible mutation in tumour tissue or plasma.
Sources for this answer
- Itovebi 3 mg & 9mg film-coated tabletsemc · SmPC Current selected SmPC · Version 3